HemaVision®: An initial screening tool for Leukemia

• Direct contact technical support
• Find products for your research

Diagnosis at the earliest stage

DNA Diagnostic manufactures HemaVision®-28Q, an initial screening tool that screens for 28 different genomic translocations associated with Leukemia. HemaVision® is a series of CE-marked in vitro diagnostic (IVD) tests designed for fast and sensitive detection of chromosomal translocations linked to Leukemia.

Advantages of the diagnostic tool

HemaVision®-28Q is an RT-qPCR screening tool that analyzes 28 translocations and up to 145 clinically relevant breakpoint regions in a simple and fast analysis, delivering results in only 4 hours. The cDNA master mix and qPCR master mix are pre-aliquoted in tube format for your qPCR instrument, ensuring easy handling and a simple procedure where you only need to add the template to start the reactions. You only need one test per patient, and positive controls are included in the kit. The setup is highly flexible, allowing you to run a single analysis or multiple analyses together, depending entirely on your needs.

Background and prevalence

Leukemia is a disease which occurs in children as well as in adults, impacting people of all ages, ethnicities, and socioeconomic backgrounds. Leukemia results from mutations in the DNA and occur when there is a mutation in the cells that normally produce blood cells in the bone marrow. These mutations lead to the uncontrolled growth of immature blood cells, which are normally immature white blood cells.

HemaVision® test utilizes total RNA extracted from whole blood or bone marrow as the starting material, ensuring a straightforward and effective process suitable for various clinical settings. Whether used for broad or targeted screening, HemaVision® delivers fast, reliable results to support accurate Leukemia diagnosis and patient care.

Early treatments impact recovery

Early diagnosis and treatment are critical in improving outcomes for leukemia patients. The earlier treatment can be initiated, the better the chances for successful management of the disease. Rapid and accurate diagnosis, followed by timely treatment, is therefore essential not only for the patients themselves but also for their families. Patients diagnosed early are more likely to respond to targeted therapies and treatments, which significantly improve survival rates and quality of life.